Subtopic Deep Dive
PRES Risk Factors and Epidemiology
Research Guide
What is PRES Risk Factors and Epidemiology?
PRES Risk Factors and Epidemiology studies the clinical precipitants like immunosuppressive drugs, eclampsia, renal failure, and sepsis, alongside incidence and recurrence patterns identified through cohort studies and meta-analyses.
PRES occurs in settings including preeclampsia/eclampsia, bone marrow transplantation, and end-stage kidney disease (Bartynski, 2008; 1075 citations). Cohort analyses link it to hypertension, immunosuppression, and sepsis (Fugate et al., 2010; 895 citations). Approximately 20-40% of cases involve atypical imaging distributions beyond posterior regions (Bartynski and Boardman, 2007; 697 citations).
Why It Matters
Risk stratification using PRES epidemiology guides preventive protocols in high-risk groups like transplant recipients and preeclamptic pregnancies, reducing neurological morbidity (Bartynski, 2008). In end-stage kidney disease patients, early recognition prevents irreversible brain injury, as PRES reversibility fails in 15-20% of cases (Canney et al., 2015; 625 citations). Low-dose aspirin prophylaxis lowers preeclampsia incidence by 80% in susceptible primigravidae, indirectly mitigating PRES risk (Wallenburg et al., 1986; 543 citations). HELLP syndrome management protocols informed by epidemiological data decrease maternal complications (Haram et al., 2009; 613 citations).
Key Research Challenges
Heterogeneous Risk Factor Attribution
PRES triggers vary across populations, complicating unified models; immunosuppressive drugs dominate post-transplant cases while eclampsia prevails in obstetrics (Bartynski, 2008). Cohort studies show overlapping etiologies like hypertension and renal failure in 60% of patients (Fugate et al., 2010). Meta-analyses struggle with publication bias in small renal cohorts (Canney et al., 2015).
Quantifying Recurrence Incidence
Recurrence rates post-initial PRES remain underreported, estimated at 5-10% in high-risk groups like preeclampsia survivors (Sibai, 2011). Long-term follow-up data lacks standardization across studies (Fischer and Schmutzhard, 2017). Offspring stroke risk from maternal preeclampsia highlights intergenerational epidemiology gaps (Kajantie et al., 2009).
Atypical PRES Reversibility Failure
Up to 20% of end-stage kidney disease PRES cases show irreversible damage despite treatment, challenging the 'reversible' nomenclature (Canney et al., 2015). Hemorrhage subtypes predict poor outcomes in 30% of anticoagulated patients (Hefzy et al., 2009). Imaging-epidemiology correlations need prospective validation (Bartynski and Boardman, 2007).
Essential Papers
Posterior Reversible Encephalopathy Syndrome, Part 1: Fundamental Imaging and Clinical Features
Walter S. Bartynski · 2008 · American Journal of Neuroradiology · 1.1K citations
Posterior reversible encephalopathy syndrome (PRES) is a neurotoxic state coupled with a unique CT or MR imaging appearance. Recognized in the setting of a number of complex conditions (preeclampsi...
Posterior Reversible Encephalopathy Syndrome: Associated Clinical and Radiologic Findings
Jennifer E. Fugate, Daniel O. Claassen, Harry J. Cloft et al. · 2010 · Mayo Clinic Proceedings · 895 citations
Distinct Imaging Patterns and Lesion Distribution in Posterior Reversible Encephalopathy Syndrome
Walter S. Bartynski, J.F. Boardman · 2007 · American Journal of Neuroradiology · 697 citations
Involvement of the frontal lobe, temporal lobe, and cerebellar hemispheres is common in PRES, along with the occasional presence of lesions in the brain stem, basal ganglia, deep white matter, and ...
Posterior Reversible Encephalopathy Syndrome in End-Stage Kidney Disease: Not Strictly Posterior or Reversible
Mark Canney, Dearbhla Kelly, Michael Clarkson · 2015 · American Journal of Nephrology · 625 citations
Posterior reversible encephalopathy syndrome (PRES) is an uncommon clinico-radiological condition that can result in severe brain injury. The pathogenesis of cerebral vasogenic edema, the hallmark ...
The HELLP syndrome: Clinical issues and management. A Review
Kjell Haram, Einar Svendsen, Ulrich Abildgaard · 2009 · BMC Pregnancy and Childbirth · 613 citations
LOW-DOSE ASPIRIN PREVENTS PREGNANCY-INDUCED HYPERTENSION AND PRE-ECLAMPSIA IN ANGIOTENSIN-SENSITIVE PRIMIGRAVIDAE
Henk C.S. Wallenburg, J. W. MAKOVITZ, G.A. Dekker et al. · 1986 · The Lancet · 543 citations
Posterior reversible encephalopathy syndrome
Marlene Fischer, Erich Schmutzhard · 2017 · Journal of Neurology · 482 citations
Reading Guide
Foundational Papers
Start with Bartynski (2008; 1075 citations) for core imaging-clinical features and triggers like eclampsia/transplants; Fugate et al. (2010; 895 citations) for associated risks in large cohorts; Bartynski and Boardman (2007; 697 citations) for lesion epidemiology.
Recent Advances
Canney et al. (2015; 625 citations) on renal PRES irreversibility; Fischer and Schmutzhard (2017; 482 citations) for updated etiology; Sibai (2011; 327 citations) on postpartum preeclampsia management.
Core Methods
Retrospective cohort analysis of imaging-clinical correlations (Fugate et al., 2010); pattern classification of MRI lesions (Bartynski and Boardman, 2007); risk prophylaxis trials like low-dose aspirin (Wallenburg et al., 1986).
How PapersFlow Helps You Research PRES Risk Factors and Epidemiology
Discover & Search
Research Agent uses searchPapers with query 'PRES risk factors eclampsia renal failure' to retrieve Bartynski (2008; 1075 citations), then citationGraph reveals 500+ citing works on epidemiology, and findSimilarPapers uncovers cohort studies like Fugate et al. (2010). exaSearch scans OpenAlex for meta-analyses on PRES incidence in transplants.
Analyze & Verify
Analysis Agent applies readPaperContent to extract risk frequencies from Fugate et al. (2010), verifies prevalence claims via verifyResponse (CoVe) against Bartynski (2008), and runs PythonAnalysis to compute meta-incidence (e.g., pandas aggregation of 20% atypical PRES rates). GRADE grading scores eclampsia evidence as high-quality from cohort data.
Synthesize & Write
Synthesis Agent detects gaps in recurrence data across renal and obstetric cohorts, flags contradictions between reversibility claims (Canney et al., 2015 vs. Bartynski, 2008), then Writing Agent uses latexEditText for risk tables, latexSyncCitations for 10-paper bibliography, and latexCompile for a review manuscript; exportMermaid generates etiology flowcharts.
Use Cases
"Run meta-analysis on PRES incidence in end-stage kidney disease patients using paper data."
Research Agent → searchPapers('PRES kidney disease') → Analysis Agent → readPaperContent(Canney 2015) → runPythonAnalysis(pandas meta-regression on incidence rates) → CSV export of pooled 15-25% risk estimate.
"Write LaTeX review on PRES risk factors in preeclampsia with citations."
Synthesis Agent → gap detection (recurrence in Sibai 2011) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(Bartynski 2008, Wallenburg 1986) → latexCompile(PDF) → outputs formatted 10-page manuscript.
"Find code for PRES imaging analysis from related papers."
Research Agent → citationGraph(Bartynski 2007) → Code Discovery → paperExtractUrls → paperFindGithubRepo(radiomics tools) → githubRepoInspect → researcher gets Python MRI segmentation scripts for lesion distribution stats.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ PRES epidemiology papers) → citationGraph clustering by risk factor → GRADE grading → structured incidence report. DeepScan applies 7-step verification: readPaperContent(Fugate 2010) → CoVe on hemorrhage risks (Hefzy 2009) → Python risk modeling. Theorizer generates hypotheses on PRES recurrence predictors from eclampsia cohorts (Kajantie 2009).
Frequently Asked Questions
What defines PRES risk factors and epidemiology?
PRES epidemiology identifies immunosuppressive drugs, eclampsia, renal failure, and sepsis as key precipitants via cohort studies (Bartynski, 2008; Fugate et al., 2010).
What are common methods in PRES epidemiology?
Methods include retrospective cohorts for incidence (Fugate et al., 2010), imaging pattern analysis (Bartynski and Boardman, 2007), and meta-reviews of risk associations (Fischer and Schmutzhard, 2017).
What are key papers on PRES risk factors?
Bartynski (2008; 1075 citations) details clinical triggers; Fugate et al. (2010; 895 citations) reports associations; Canney et al. (2015; 625 citations) covers renal cases.
What open problems exist in PRES epidemiology?
Challenges include unstandardized recurrence tracking, atypical irreversibility mechanisms (Canney et al., 2015), and prospective validation of intergenerational risks (Kajantie et al., 2009).
Research Neurological Complications and Syndromes with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching PRES Risk Factors and Epidemiology with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers